Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 443-455 , August 2010

Optimising the strategy of care in early rheumatoid arthritis

  • James Dale, MBChB, MRCP (Clinical Research Fellow)

      Affiliations

    • Tel.: +44 141 211 3008; Fax: +44 141 211 0054.
    • ,
  • Duncan Porter, BA, MBChB, MRCP (Senior Lecturer and Honorary Consultant Rheumatologist)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 141 211 3429; Fax: +44 141 211 0054.

References 

  1. McGonagle D, Conaghan P, O'Connor P, et al. The relationship between synovitis and bone changes in early untreated arthritis. Arthritis Rheum. 1999;42:1706–1711
  2. Van der Horst-Bruinsma I, Speyer I, Visser H, et al. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol. 1998;37:1084–1088
  3. Saag K, Teng G, Patkar N, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–784
  4. National Collaborating Centre for Chronic Conditions . Rheumatoid arthritis: national clinical guideline for management and treatment in adults. Royal College of Physicians; February 2009;
  5. Eberhardt K, Fex E. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol. 1998;37:1324–1329
  6. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single drug or combination disease modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46:894–898
  7. Finckh A, LLang MH, van Herckenrode CM, Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55:864–872
  8. Scott DL, Smith C, Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol. 2003;21(Suppl. 31):S20–S27
  9. Symmons DP, Jones MA, Scott DL, Prior P. Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol. 1998;25:1072–1077
  10. Egsmose C, Lund B, Borg G, et al. Patients with early rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective, double blind, placebo controlled study. J Rheumatol. 1995;22:2208–2213
  11. Anderson JJ, Wells G, Verhoeven A, Felson D. Factors predicting response to treatment in rheumatoid arthritis. The importance of disease duration. Arthritis Rheum. 2000;43:22–29
  12. Munro R, Hampson R, McEntegart A, et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis. 1998;57:88–93
  13. Green M, Marzo-Ortega H, McGonagle D, et al. Persistence of mild, early inflammatory arthritis. The importance of disease duration, rheumatoid factor and the shared epitope. Arthritis Rheum. 1999;42:2184–2188
  14. Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease modifying antirheumatic drugs is sustained over time. Arthritis Rheum. 2009;60:1222–1231
  15. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977
  16. Conaghan P, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage. A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum. 2003;48:64–71
  17. Wick MC, Lindblad S, Klareskog L, van Vollenhoven RF. Relations between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description. Ann Rheum Dis. 2004;63:848–852
  18. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet. 2004;364:263–269
  19. Verstappen SMM, Jacobs JWG, van dr Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open label strategy trial). Ann Rheum Dis. 2007;66:1443–1449
  20. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study). Arthritis Rheum. 2005;52:3381–3390
  21. Mottonen T, Hannonen , Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet. 1999;353:1568–1573
  22. Choy EHS, Smith C, Dore CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology. 2005;44:1414–1421
  23. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309–318
  24. Williams R, Walsh D, Hassel A, et al. Early rheumatoid arthritis network (ERAN) audit of ARMA standards of access to rheumatology services for patients with early RA. Rheumatology. 2006;45(Suppl. 1):i56
  25. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124–134
  26. Choi HK, Hernan MA, Seegar JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–1177
  27. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis – no benefit from of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold. J Rheumatol. 1993;20:645–649
  28. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulphasalazine or a combination of the three medications. Results of a two year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1164–1170
  29. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med. 1995;333:137–141
  30. Stein CM, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open label extension study. Arthritis Rheum. 1997;40:1843–1851
  31. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable dose methotrexate. Ann Intern Med. 2002;137:726–733
  32. Lehman AJ, Esdaile JM, Klinchoff AV, et al. A 48 week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis. Results of the METGO Study. Arthritis Rheum. 2005;52:1360–1370
  33. Haagsma CJ, van Riel PLCM, de Jong AJL, Van de Putte LBA. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997;36:1082–1088
  34. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220–225
  35. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs. Five year experience from the FIN-RACo Study. Arthritis Rheum. 2004;50:2072–2081
  36. Puolakka K, Kautiainen H, Mottonen T, et al. Impact of initial aggressive drug treatment with a combination of work disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis. A five-year randomized follow-up trial. Arthritis Rheum. 2004;50:55–62
  37. Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time. The eleven-year results of the Finnish Rheumatoid Arthritis Combination Therapy Trial. Arthritis Rheum. 2009;60:1222–1231
  38. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination with methotrexate, cyclosporine and intra-articular betamethasone compared with methotrexate and intra-articular betamethasone in early, active rheumatoid arthritis. An investigator-initiated, randomized, double-blind, parallel group, placebo-controlled study. Arthritis Rheum. 2006;54:1401–1409
  39. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008;67:815–822
  40. Marchesoni A, Battafarano N, Arreghini M, et al. Radiographic progression in early rheumatoid arthritis: a 12 month randomized controlled study comparing the combination of cyclosporine and methotrexate with methotrexate alone. Rheumatology. 2003;42:1545–1549
  41. Landewe RBM, Boers M, Verhoeven AC, et al. COBRA Combination therapy in patients with early rheumatoid arthritis. Long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46:347–356
  42. Goekoop-Ruiterman YPM, de vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis. A randomized trial. Ann Intern Med. 2007;146:406–415
  43. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early, active rheumatoid arthritis. A randomized, single blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58:1310–1317
  44. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the management of rheumatoid arthritis (the first 2 years). Rheumatology. 2007;45:1167–1169
  45. St Clair EW, van der Heidje DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–3443
  46. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER Study. A multicenter, randomized double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalumimab alone in patients with early, aggressive rheumatoid arthritis who had not received methotrexate treatment. Arthritis Rheum. 2006;54:26–37
  47. Emery P, Breedveld F, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexare and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–382
  48. Prior P, Symmons DPM, Scott DL, et al. Cause of death in rheumatoid arthritis. Br J Rheumatol. 1984;23:92–99
  49. Wolfe F, Mitchel DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–494
  50. Ikeda K, Cox S, Emery P. Biological therapy in early arthritis – overtreatment or the way to go?. Arthritis Res Ther. 2007;9:211–217
  51. Bongatz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–2285
  52. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy. Arthritis Rheum. 2006;54:2368–2376
  53. Dixon WG, Symmons DPM, Lunt M, et al. Serious infection following anti-tumour necrosis factor alpha therapy in patients with rheumatoid arthritis. Lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56:2896–2904
  54. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin Infect Dis. 2004;38:1261–1265
  55. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors may predispose to significant increases in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–2127
  56. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703
  57. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421–1426
  58. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1414–1420
  59. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Results from a twelve-month randomized, double-blind, placebo controlled trial. Arthritis Rheum. 2005;52:27–35
  60. Sheehy C, Murphy E, Duffy T, Barry M. Remission induction with etanercept and methotrexate in very early rheumatoid arthritis with sustained remission after etanercept withdrawal. Arthritis Rheum. 2008;58(Suppl.):S918
  61. Van der Bijl AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007;56:2129–2134
  62. Rigby WF, Ferracciolo G, Greenwald M, et al. Rituximab improved physical function and quality of life in patients with early rheumatoid arthritis; results from a randomized active comparator placebo-controlled trial of rituximab in combination with methotrexate compared to methotrexate alone. Ann Rheum Dis. 2009;68(Suppl. 3):581
  63. Westhovens R, Robles M, Ximes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;
  64. Nielen MMJ, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis. A study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380–386
  65. El-Gabalawy H. The preclinical stages of RA: lessons from human studies and animal models. Best Pract Res Clin Rheumatol. 2009;23:49–58
  66. Chibnik LB, Mandl LA, Costenbader KH, et al. Continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol. 2009;36:706–711
  67. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008;58:3000–3008
  68. Van der Linden MPM, van der Woude D, Ioan-Facsinay A, et al. Value of anti-modified citrullinated vimentin and third generation anti-cyclic citrullinated peptide compared with second generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum. 2009;60:2232–2241
  69. Van Aken J, van Dongen H, le Cessie S, et al. Comparison of long-term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis. 2006;65:20–25
  70. Van der Helm-van Mil AHM, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recent onset undifferentiated arthritis. Moving towards individualized treatment decisions. Arthritis Rheum. 2008;58:2241–2247
  71. Narvaez J, Sirvent E, Antonio Narvaez J, et al. Usefulness of magnetic resonance imaging of the hand versus anti-cyclic citrullinated peptide antibody testing to confirm the diagnosis of clinically suspected early rheumatoid arthritis in the absence of rheumatoid factor and radiographic erosions. Semin Arthritis Rheum. 2008;38:101–109
  72. Eshed I, Feist E, Althoff CE, et al. Tenosynovitis of the flexor tendons of the hand detected by MRI: an early indicator of rheumatoid arthritis. Rheumatology. 2009;48:887–891
  73. Khanna D, Oh M, Furst DE, et al. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum. 2007;57:440–447
  74. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission. Evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761–3773
  75. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58:2958–2967
  76. Szkudlarek M, Court-Payen M, Strandberg C, et al. Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: a comparison with dynamic magnetic resonance imaging. Arthritis Rheum. 2001;44:2018–2023
  77. Walther M, Harms H, Krenn V, et al. Correlation of power Doppler sonography with vascularity of the synovial tissue of the knee joint in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 2001;44:331–338
  78. Naredo E, Moller I, Cruz A, et al. Power Doppler ultrasonographic monitoring of response to anti-tumour necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:2248–2256
  79. Naredo E, Collodo P, Cruz A, et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum. 2007;57:116–124
  80. Sheel AK, Hermann KGA, Kahler E, et al. A novel ultrasonographic synovitis scoring system suitable for analysing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2005;52:733–743
  81. Ohrndorf S, Kellner H, Strunk J, et al. Evaluation of a novel 7 joint sonographic score (US7) in daily rheumatologic practice – 6 months results of multi center project in Germany. Arthritis Rheum. 2008;58(Suppl.):S464
  82. Naredo E, Rodriguez M, Campos C, et al. Validity, reproducibility and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2008;59:515–522
  83. Emery P, McInnes IB, van Vollenhoven R, Kraan MC. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology. 2008;47:392–398
  84. Plant MJ, Williams AL, O'Sullivan MM, et al. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:1473–1477
  85. Innala L, Kokkonen H, Eriksson C, et al. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinate peptides. J Rheumatol. 2008;35:1002–1008
  86. Rioja I, Hughes FJ, Sharp CH, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients. CXCL13, CCL23, transforming growth factor α, tumour necrosis factor receptor superfamily member 9 and macrophage colony-stimulating factor. Arthritis Rheum. 2008;58:2257–2267
  87. Marotte H, Gineyts E, Miossec P, Delma PD. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68:1197–1200
  88. Van Tuyl LHD, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot study. Ann Rheum Dis. 2008;67:1574–1577
  89. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412–1419
  90. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis. A twelve-month, multicenter, randomized, double-blind, placebo controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299;–1309

PII: S1521-6942(09)00145-4

doi: 10.1016/j.berh.2009.11.009

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 443-455 , August 2010

Article Tools

* Image Usage & Resolution